Stock Chart

GERN

$1.67 +0.30%
Score: 59.2 HOLD
1Y Target $1.70 +2.1%
i
1Y Price Target

This target is derived from long-term trendline analysis and projected growth.

Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.

Target may adjust dynamically as the stock trend reverses or accelerates.
LEAPs: SELL $2
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $2
Premium: $0.55
Expiry: Jan 15, 2027
Target: $1
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $1.17 - $1.81 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.62
Vol: 0.72x (vs SPY: 2.0x | vs QQQ: 1.6x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About GERN - Geron Corp

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products …

Key Statistics

Market Cap $954M

This GERN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track GERN's price movements with trendlines, gamma walls, and key support/resistance levels.